Test Catalog

Interpretive Handbook

Test 83092 :
Lupus Anticoagulant Profile

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Lupus anticoagulant (LAC) is an antibody to negatively charged phospholipid that interferes with phospholipid-dependent coagulation tests.  


LAC is found in, but not limited to, patients with systemic lupus erythematosus; LAC is associated with other autoimmune disorders and collagen vascular disease, and occurs in response to medications or certain infections (eg, respiratory tract infections in children) and in individuals with no obvious underlying disease.


LAC has been associated with arterial and venous thrombosis and fetal loss. Individuals with thrombocytopenia or factor II deficiency associated with LAC may be at risk for bleeding.

Useful For Suggests clinical disorders or settings where the test may be helpful

Confirming or excluding presence of lupus anticoagulant (LAC) distinguishing LAC from specific coagulation factor inhibitors and nonspecific inhibitors


Investigation of a prolonged activated thromboplastin time, especially when combined with other coagulation studies

Interpretation Provides information to assist in interpretation of the test results

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

This test is not useful for the detection of antiphospholipid antibodies that do not affect coagulation tests. We recommend separate testing for serum phospholipid (cardiolipin) antibodies.


Patient should not be receiving warfarin or heparin. If the patient is currently on warfarin or heparin, this should be noted, treatment with heparin causes false-positive results of in vitro coagulation testing for lupus anticoagulant. Coumadin treatment may impair ability to detect the more subtle varieties of lupus-like anticoagulants.

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.


10.3-12.8 seconds




The INR is used only for patients on stable oral anticoagulant therapy. It makes no significant contribution to the diagnosis or treatment of patients whose PT is prolonged for other reasons.



Adults: 26-36 seconds

The normal full-term newborn APTT may be up to 35% longer than in adults and even longer (up to twice the adult upper limit) in healthy premature infants. Typically, the APTT is in the adult reference range by age 3 months in healthy full-term infants and by age 6 months in healthy premature infants (30-60 weeks gestation)*.

26-36 seconds (>3-6 months)

*See Pediatric Hemostasis References in Coagulation Studies in Special Instructions.




Clinical References Provides recommendations for further in-depth reading of a clinical nature

1. Arnout J, Vermylen J: Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease. J of Thromb Haemost 2003 May;1(5):931-942

2. Levin JS, Branch DW, Rauch J: The antiphospholipid syndrome. New Engl J Med 2002 March 7;346(10):752-763

3. Proven A, Bartlett RP, Moder KG et al: Clinical importance of positive tests for lupus anticoagulant and anticardiolipin antibodies. Mayo Clin Proc 2004,79(4):467-475

Tell Us What You Think